MIL-100(Fe)-based Co-delivery platform as cascade synergistic chemotherapy and immunotherapy agents for colorectal cancer via the cGAS-STING pathway
Acta Biomaterialia · 2025-09 · 204 · 582-595
DOI: 10.1016/j.actbio.2025.08.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2025-09. Verfasst von Pai Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin 130021, China. Hauptthemen laut MEDLINE: Immunotherapy, Membrane Proteins, Colorectal Neoplasms, Nucleotidyltransferases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Education Department of Jilin Province, Department of Science and Technology of Jilin Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a major global health burden as the third most commonly diagnosed malignancy and the second leading cause of cancer-related mortality worldwide. While combination chemotherapy and immune agonists hold potential to overcome tumor heterogeneity through multi-pathway modulation, their therapeutic efficacy remains limited by off-target drug distribution and immunosuppressive tumor microenvironment (TME). To address this, we developed a tumor-targeted chemo-immunotherapy platform by encapsulating irinotecan (CPT-11) and resiquimod (R848) in hyaluronic acid (HA) coated MIL-100(Fe) metal-organic frameworks (CRMH NPs), enabling CD44-mediated delivery and synergistic anti-tumor responses. The system enabled controlled drug release in the acidic TME, promoting immunogenic cell death (ICD), inducing the cGAS-STING pathway and activating immune cells. In vitro, CRMH NPs induced significant ICD, as evidenced by the release of damage-associated molecular patterns (DAMPs) like high mobility group box 1 (HMGB1) and calreticulin (CRT), and matured dendritic cells (DCs), which triggered by TLR7 agonist, enhancing immune responses. It also activated the cGAS-STING pathway, which could efficiently induce the targeted cells to produce type I interferon (IFN) and proinflammatory cytokines, thereby enhancing T cell activation and recruitment. In vivo, CRMH NPs significantly reduced tumor growth in CT26 mouse models, activated innate immune signaling, and increased immune cell infiltration, demonstrating superior anti-tumor effects compared to free drugs and other nanoparticle formulations. Furthermore, CRMH NPs upregulated PD-L1 expression on tumor cells, suggesting potential synergy with immune checkpoint blockade therapy. Combining CRMH NPs with anti-PD-L1 therapy enhanced anti-tumor immunity, particularly in distant tumors, highlighting a promising approach to overcoming immune evasion and achieving durable tumor regression. These findings supported CRMH NPs as a versatile and effective platform for chemo-immunotherapy in CRC. STATEMENT OF SIGNIFICANCE: Colorectal cancer (CRC) remains a major global health challenge with limited treatment efficacy due to tumor heterogeneity and immunosuppression. This study introduces a novel tumor-targeted nanoparticle platform, CRMH NPs, which co-deliver the chemotherapeutic drug irinotecan (CPT-11) and the immune agonist resiquimod (R848) using hyaluronic acid-coated MIL-100(Fe) metal-organic frameworks. CRMH NPs enhance drug delivery, induce immunogenic cell death, and activate the cGAS-STING pathway, synergizing chemotherapy and immunotherapy. Demonstrating superior tumor suppression and immune activation in preclinical models, this platform overcomes key limitations of current therapies, such as off-target effects and immune evasion. Its combination with anti-PD-L1 therapy further improves outcomes, offering a promising strategy for durable CRC treatment. This work advances nanomedicine and immuno-oncology, providing a transformative approach for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
- College of Basic Medical Sciences, the Medical Basic Research Innovation Center of Airway Disease in North China, Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China.
- Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China.
- College of Basic Medical Sciences, the Medical Basic Research Innovation Center of Airway Disease in North China, Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China. Electro…
- Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin 130021, China. Electronic address: wquan@jlu.edu.cn.
- Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China; State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Xiamen Univer…
Förderung
- National Natural Science Foundation of China
- Education Department of Jilin Province
- Department of Science and Technology of Jilin Province
- Jilin University
- Changchun Institute of Applied Chemistry, Chinese Academy of Sciences
- First Hospital of Jilin University
Zitieren
APA
Wang, P., Liu, H., Guo, L., Tang, Y., Lan, T., Zhou, R., Xu, H., Wang, L., Wang, X., Chen, B., Wang, Y., Wang, S., Liu, C., Chen, J., Xu, C., Wang, Q., & Tian, H. (2025). MIL-100(Fe)-based Co-delivery platform as cascade synergistic chemotherapy and immunotherapy agents for colorectal cancer via the cGAS-STING pathway. Acta Biomaterialia, 204, 582-595. https://doi.org/10.1016/j.actbio.2025.08.021
Vancouver
Wang P, Liu H, Guo L, Tang Y, Lan T, Zhou R, et al. MIL-100(Fe)-based Co-delivery platform as cascade synergistic chemotherapy and immunotherapy agents for colorectal cancer via the cGAS-STING pathway. Acta Biomaterialia. 2025;204:582-595. doi:10.1016/j.actbio.2025.08.021
BibTeX
@article{Wang2025,
author = {Wang, Pai and Liu, Heshi and Guo, Lei and Tang, Yixin and Lan, Tianwei and Zhou, Rui and Xu, Huiqing and Wang, Lu and Wang, Xue and Chen, Baiqiao and Wang, Yixing and Wang, Siyuan and Liu, Chang and Chen, Jie and Xu, Caina and Wang, Quan and Tian, Huayu},
title = {MIL-100(Fe)-based Co-delivery platform as cascade synergistic chemotherapy and immunotherapy agents for colorectal cancer via the cGAS-STING pathway},
journal = {Acta Biomaterialia},
year = {2025},
volume = {204},
pages = {582--595},
doi = {10.1016/j.actbio.2025.08.021}
}
EUVIMED